COMMUNIQUÉS West-GlobeNewswire

Tresiba® reduces hypoglycaemia regardless of blood sugar level
07/12/2017
Abu Dhabi, UAE, 7 December 2017 - People with either type 1 or type 2 diabetes treated with Tresiba ® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of [...]
Ryzodeg® significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan
07/12/2017
Abu Dhabi, UAE, 7 December 2017 - In people with type 2 diabetes who fast during Ramadan, Ryzodeg ® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe [...]
PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S
07/12/2017
Copenhagen, 2017-12-07 08:01 CET (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, [...]
OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
07/12/2017
Independent Data Monitoring Committee recommends future recruitment focused on patients who have previously failed immune checkpoint inhibitor treatment New strategy adjusts for rapidly-evolving clinical practice with [...]
ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION
07/12/2017
GHENT, Belgium, 7 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from the Phase III [...]
Novartis tender offer for Advanced Accelerator Applications commences
07/12/2017
Basel, December 7, 2017 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), [...]
INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2018
07/12/2017
Innate Pharma announceS ITS FINANCIAL CALENDAR FOR 2018 Marseille, France, December 7, 2017, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces its financial calendar for [...]
INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018
07/12/2017
INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018 Marseille, le 7 décembre 2017, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui son calendrier financier pour l'année 2018 : 8 [...]
INNATE PHARMA : NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT DECEMBER 4, 2017
07/12/2017
NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT December 4, 2017 Marseille, France, December 7, 2017, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 [...]
INNATE PHARMA : NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 4 DECEMBRE 2017
07/12/2017
nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 4 décembre 2017 Marseille, le 7 décembre 2017, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $276 Million
07/12/2017
LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]
Resverlogix Repays $68.8 Million Loan
07/12/2017
CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX ) announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of [...]
Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
07/12/2017
SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to [...]
Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
06/12/2017
PHILADELPHIA and NEW YORK, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. ( [...]
G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2017
RESEARCH TRIANGLE PARK, N.C., Dec. 06, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced the grant of an equity inducement award to Barclay (Buck) [...]
Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
06/12/2017
BURLINGTON, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President [...]
US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
06/12/2017
SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses [...]
Purepoint Uranium Closes Final Tranche of $1,200,000 Private Placement
06/12/2017
Not for Dissemination in the United States or through U.S. Newswire Services TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (TSXV:PTU) (the “ Company ”) is pleased to announce the closing of the [...]
Analogic Announces Results for the First Quarter Ended October 31, 2017 and Declares Quarterly Cash Dividend
06/12/2017
PEABODY, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq: ALOG ), enabling the world's medical imaging and aviation security technology, today announced results for its first quarter ended October [...]

Pages